Microsteps for Health Behaviors

Age: 18 - 65

Sex: Any

Trial Phase: Academic

Sponsor: Stanford University

Must be taking: GLP-1RA

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

6000 Participants Needed

Trial Summary

What is the purpose of this trial?

This study evaluates the effect of single exposure to written Microsteps messages, and short video booster content, on behavioral expectation to adopt behavioral nudges, immediately after exposure, as well as self-reported behavioral adoption of those nudges, two weeks later. Beyond that, the study will examine post-exposure hope and happiness as well as voluntary post-trial engagement with the health messages. This study will be conducted entirely online. Adult participants, living in the US and the UK, will be recruited through the platform Prolific Academic (ProA).

Research Team

Maya Adam, MD

Principal Investigator

Stanford University

Eligibility Criteria

This trial is for adults in the US and UK who are registered with Prolific Academic and currently using GLP-1RA medication. There are no specific exclusion criteria, making it broadly accessible to those meeting the inclusion conditions.

Inclusion Criteria

Participants must be living in US and UK

Registered with the Prolific Academic platform

I am currently taking a GLP-1 receptor agonist medication.

Exclusion Criteria

Not applicable.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1 week

Intervention

Participants are exposed to written Microsteps messages and either an instructional or storytelling video, followed by a questionnaire to assess behavioral expectations and emotional responses

1 day

Online session

Follow-up

Participants complete a self-reported behavioral adoption questionnaire and assess changes in hope and happiness

2 weeks

Online follow-up

Treatment Details

Interventions

• Instructional Video
• Microsteps
• Storytelling video

Trial Overview The study is testing whether a single exposure to written 'Microsteps' messages and short video content can influence people's expectations to adopt health behavior nudges immediately after viewing, as well as actual adoption two weeks later. It also looks at hope, happiness, and engagement post-trial.

Participant Groups

Group I: Written messages of Microsteps and Storytelling video Experimental Treatment 2 Interventions

Participants will be shown written Microsteps messages presenting various behavioral nudges, as well as a short, animated storytelling video. Thereafter, they will be asked to complete the questionnaire assessing their behavioral expectation of adopting the behavioral nudges and two visual analogue scales measuring hope and happiness. Two weeks later, participants in all three arms will be asked to return and complete the self-reported behavioral adoption questionnaire.

Group II: Written messages of Microsteps and Instructional video Experimental Treatment 2 Interventions

Participants will be shown written Microsteps messages presenting various behavioral nudges and a short instructional video. Thereafter, they will be asked to complete a questionnaire to assess their behavioral expectation of adopting the behavioral nudges and two visual analogue scales measuring hope and happiness. Two weeks later, participants in all three arms will be asked to return and complete the self-reported behavioral adoption questionnaire.

Group III: Do-nothing Control Group Active Control 1 Intervention

Participants will not be exposed to either the microsteps or video content before they are asked to complete the questionnaire assessing their behavioral expectation of adopting the behavioral nudges and two visual analogue scales measuring hope and happiness. Two weeks later, participants in all three arms will be asked to return and complete the self-reported behavioral adoption questionnaire.

Who Is Running the Clinical Trial?

Stanford University

Lead Sponsor

Trials

2,527

Recruited

17,430,000+